Life Sciences

  • June 04, 2026

    Generics Cos. Get More Freedom In High Court Patent Ruling

    The U.S. Supreme Court's decision Thursday shutting down a patent case involving a generic heart drug that uses a so-called skinny label establishes a road map for generics companies to avoid such suits and creates hurdles for branded companies pursuing infringement litigation, attorneys say.

  • June 04, 2026

    Amgen Won't Face 'Nonsensical' Rodent Antibody IP At Trial

    A Delaware federal judge has trimmed Harbour Medical's infringement suit against an Amgen unit just days before trial, saying two of the company's mouse antibody patents are indefinite based on a term that "everyone agrees" is "nonsensical."

  • June 04, 2026

    Eli Lilly's 'Overbroad' Weight Drug TM Deal Rejected

    A Washington federal judge has refused to sign off on a deal to settle trademark claims brought by Eli Lilly against two Seattle-area medical clinics, saying the associated consent decree was "overbroad" and contained an even more sweeping injunction.

  • June 04, 2026

    Doctor Lied About Risky 'Basket Weave' Surgery, Patients Say

    Six patients accused a Seattle doctor of overstating his "basket weave" surgery technique meant to treat a painful condition known as "slipping rib syndrome," claiming in a Washington state lawsuit that Dr. Madhankumar Kuppusamy failed to disclose the experimental nature of the procedure that left some patients with serious injuries.

  • June 04, 2026

    Legislative Update: Cannabis And Psychedelics Bill Roundup

    New York lawmakers gave final approval to legislation designed to curb the flow of illicit product into the state's cannabis market; Iowa's governor signed into law a bill to double the number of licensed medical cannabis dispensaries; and Louisiana legislation allowing terminally ill patients to access medical marijuana became law. Here are the major moves in cannabis and psychedelics legislation from the past week.

  • June 04, 2026

    Fed. Circ. Invalidates Spinal Implant Patent Claims

    The Federal Circuit on Thursday invalidated patent claims covering parts used to make expandable implant devices in spinal fusion surgeries that were the basis of a $9.5 million jury verdict against Life Spine Inc. and that had been upheld by the Patent Trial and Appeal Board.

  • June 04, 2026

    Judge Questions Fees In Abbott Investors' $40M Formula Deal

    An Illinois federal judge on Thursday granted final approval to most of Abbott Laboratories' $40 million deal to resolve shareholder claims over its management of a 2022 infant formula crisis, but questioned whether the settlement's corporate reforms justify a $15 million fee award for the investors' attorneys.

  • June 04, 2026

    Inotiv Gets Cash Access To Pursue Ch. 11 Prepack Track

    Bankrupt drug research and development company Inotiv Inc. received interim approval on Thursday to access a $25 million bankruptcy loan as it pursues a prepackaged balance sheet restructuring in Texas court.

  • June 04, 2026

    Catalent Investors Say No Objections To $78M Deal, Fee Bid

    Investors seeking final approval of a $78 million securities fraud settlement with Catalent told a New Jersey federal court that the proposed deal and fee bid are free of objections, arguing the positive response further supports the court's approval of the settlement.

  • June 04, 2026

    US Middle Market PE Surge Expected After Strong 2025

    U.S. middle market private equity dealmakers are signaling renewed optimism, with the vast majority expecting a meaningful jump in buyout activity over the next two years after a robust 2025, according to survey results published on Thursday. 

  • June 04, 2026

    Supreme Court Shuts Down 'Skinny Label' Drug Patent Suit

    The U.S. Supreme Court on Thursday ended a patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, saying Amarin Pharma Inc. had not plausibly alleged that Hikma encouraged healthcare providers to infringe its patents.

  • June 03, 2026

    AbbVie Loses Miss. Discount Drug Law Challenge For Good

    A Mississippi federal judge on Wednesday threw out a suit brought by AbbVie and other pharmaceutical manufacturers that participate in Medicaid challenging a law barring their interference with the distribution of discounted prescriptions to pharmacies serving low-income patients.

  • June 03, 2026

    Medtronic Unit Must Face Bellwether Hernia Mesh Claims

    A Massachusetts federal judge has largely cleared the way for bellwether claims in multidistrict litigation over Covidien's hernia mesh, finding that a reasonable jury could find the Medtronic subsidiary failed to adequately warn physicians about certain risks.

  • June 03, 2026

    Balwani Takes Theranos Conviction Challenge To Justices

    Former Theranos executive Ramesh "Sunny" Balwani is asking the U.S. Supreme Court to review his criminal fraud conviction and nearly 13-year prison sentence, arguing that the Ninth Circuit used the wrong review doctrine in rejecting his argument that prosecutors had failed to correct allegedly false testimony given by investor victims.

  • June 03, 2026

    'This Is Their Document': Jury Told J&J Docs Prove Talc Lies

    Counsel for the families of three women who died of ovarian cancer delivered closing arguments Wednesday in their six-week-long bellwether lawsuit against Johnson & Johnson, telling jurors that decades-old internal documents prove the company hid that its talc was contaminated with asbestos.

  • June 03, 2026

    Squires Institutes 3 Patent Reviews, Denies 3 Others

    U.S. Patent and Trademark Office Director John Squires on Tuesday granted three requests for review of patents under the America Invents Act, while turning down three other petitions.

  • June 03, 2026

    Ill. Court Blocks Fla. Suit Targeting Gender Care Policies

    An Illinois federal judge blocked the Florida attorney general's lawsuit targeting medical groups' policies on youth gender-affirming care, saying there's sufficient jurisdiction over Sunshine State officials because of a potential nationwide chilling effect the enforcement action caused.

  • June 03, 2026

    Trans Youth Sue NYU Langone, DOJ To Bar Records Release

    A group of transgender minors and young adults who received gender dysphoria care at NYU Langone urged a New York federal court to bar the U.S. Department of Justice from accessing their sensitive health records through a criminal subpoena.

  • June 03, 2026

    Purdue Pharma Heir Sues Son Over Sackler Matriarch's Estate

    Former Purdue Pharma LP President Richard Sackler has appealed a Connecticut probate court decision favoring his son David Sackler in a dispute over his mother Beverly Sackler's estate, saying a judge ignored self-dealing rules when approving his son's request to assign trust interests to a public charity.

  • June 03, 2026

    BigLaw Insider Trading Defendants Have Big-Name Legal Help

    An insider trading case involving nonpublic information prosecutors say was stolen from some of the largest law firms in the U.S. has ensnared more than two dozen defendants, many of whom have turned to lawyers with notable clients including Donald Trump, Harvey Weinstein and Luigi Mangione.

  • June 03, 2026

    1st Circ. Panel Seems Poised To Uphold RI Drug Pricing Law

    The majority of a First Circuit panel seemed unlikely Wednesday to upend a Rhode Island law that blocks drug manufacturers from imposing restrictions on healthcare providers and contract pharmacies in a federal prescription drug discount program, appearing unconvinced of an argument that states can't interfere with federal government programs. 

  • June 03, 2026

    Supplier Can't Force Arbitration Of Worker's Wage Suit

    A proposed wage class action against a medical and industrial gas supplier can proceed in court, a Washington federal judge ruled, finding that a former worker's arbitration agreement with a staffing agency did not apply.

  • June 03, 2026

    IVF Patients Say Natera Profited Off Ineffective Embryo Tests

    A proposed class of in vitro fertilization patients are suing Natera Inc. in California federal court, alleging that it falsely advertised the efficacy and importance of its preimplantation genetic testing to rake in hundreds of millions of dollars from patients looking to conceive.

  • June 03, 2026

    Drug Research Co. Inotiv Files Ch. 11 To Cut $325M In Debt

    Contract drug research and development company Inotiv Inc. filed a prepackaged Chapter 11 case Wednesday in Texas bankruptcy court with $489 million of debt and support from the majority of its creditors for its reorganization plan.

  • June 03, 2026

    Paul Weiss Hires Deals Pro From Dechert In NY

    Paul Weiss Rifkind Wharton & Garrison LLP announced Monday that it has welcomed a corporate partner from Dechert LLP, touting his role in large mergers and acquisitions in the life sciences, financial services, consumer and retail, energy, technology and industrial sectors.

Expert Analysis

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Software Patents May Face New Eligibility Scrutiny

    Author Photo

    November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

  • Riding The Changing Winds For AI Innovations At The USPTO

    Author Photo

    As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.

  • Series

    The Law Firm Merger Diaries: Integrating Practice Groups

    Author Photo

    Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.

  • Opinion

    Supreme Court Term Limits Would Carry Hidden Risk

    Author Photo

    While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Next Steps For Orgs. Amid Updated OpenAI Usage Policies

    Author Photo

    OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.

  • Series

    Knitting Makes Me A Better Lawyer

    Author Photo

    Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.